We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gut Microbiome Dysbiosis Linked to COVID-19

By LabMedica International staff writers
Posted on 07 Nov 2022
Image: The NucleoSpin Soil Kit for isolating DNA from stools (Photo courtesy of Macherey-Nagel)
Image: The NucleoSpin Soil Kit for isolating DNA from stools (Photo courtesy of Macherey-Nagel)

Previous reports have demonstrated that severe COVID-19 is frequently associated with specific inflammatory immune phenotypes, lymphopenia, and a generally disproportionate immune response leading to systemic organ failure.

Complex gut microbiota ecosystems can prevent the invasion of potentially pathogenic bacteria. Conversely, when the gut microbiota incurs damage, such as through antibiotics treatment, competitive exclusion of pathogens is weakened and potentially dangerous blooms of antibiotic-resistant bacterial strains can occur.

Medical Microbiologists at the New York University Grossman School of Medicine (New York, NY, USA) and their colleagues demonstrated that SARS-CoV-2 infection induces gut microbiome dysbiosis in mice, which correlated with alterations to Paneth cells and goblet cells, and markers of barrier permeability. They then they analyzed the bacterial composition of stool samples from 96 adults hospitalized with COVID-19 in 2020.

For bacterial DNA extraction 700 µL of SL1 lysis buffer (NucleoSpin Soil kit, Macherey-Nagel, Allentown, PA, USA) was added to the stool samples and tubes were heated at 95 °C for two hours to inactivate SARS-CoV-2. DNA concentration was assessed using a NanoDrop spectrophotometer. Human samples were prepared using KAPA HiFi Polymerase to amplify the V4 region of the 16 S rRNA gene. Libraries were sequenced on a MiSeq (Illumina, San Diego, CA, USA) using paired-end 2 × 250 reads and the MiSeq Reagent Kitv2.

The investigators observed an increase in populations of several microbes known to include antibiotic-resistant species. An analysis of stool samples paired with blood cultures found that antibiotic-resistant bacteria in the gut migrated to the bloodstream in 20% of patients. This migration could be due to a combination of the immune-compromising effects of the viral infection and the antibiotic-driven depletion of commensal gut microbes. The team reported that members of the phyla Firmicutes and Bacteroidetes represented the most abundant bacteria, followed by Proteobacteria.

The authors concluded that their findings support a scenario in which gut-to-blood translocation of microorganisms following microbiome dysbiosis leads to dangerous bloodstream infection during COVID-19, a complication seen in other immunocompromised patients, including patients with cancer, acute respiratory distress syndrome, and in ICU patients receiving probiotics. The study was published November 1, 2022 in the journal Nature Communications.

Related Links:
New York University Grossman School of Medicine 
Macherey-Nagel 
Illumina 

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Automated PCR Setup
ESTREAM

DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
PURITAN MEDICAL